MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

A. J M Ferreri; S. Dell&apos;Oro; M. Foppoli; M. Bernardi; A. A. Brandes; A. Tosoni; M. Montanari; M. Balzarotti; M. Spina; F. Ilariucci; F. Zaja; C. Stelitano; F. Bobbio; G. Corazzelli; L. Baldini; M. Ponzoni; P. Picozzi; F. Caligaris Cappio; M. Reni

doi:10.1212/01.wnl.0000210464.94122.e1

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

A. J M Ferreri, S. Dell'Oro, M. Foppoli, M. Bernardi, A. A. Brandes, A. Tosoni, M. Montanari, M. Balzarotti, M. Spina, F. Ilariucci, F. Zaja, C. Stelitano, F. Bobbio, G. Corazzelli, L. Baldini, M. Ponzoni, P. Picozzi, F. Caligaris Cappio, M. Reni

Research output: Contribution to journal › Article › peer-review

Abstract

The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ± 7%) was obtained.

Original language	English
Pages (from-to)	1435-1438
Number of pages	4
Journal	Neurology
Volume	66
Issue number	9
DOIs	https://doi.org/10.1212/01.wnl.0000210464.94122.e1
Publication status	Published - May 2006

ASJC Scopus subject areas

Neuroscience(all)

Access to Document

10.1212/01.wnl.0000210464.94122.e1

Cite this

Ferreri, A. J. M., Dell'Oro, S., Foppoli, M., Bernardi, M., Brandes, A. A., Tosoni, A., Montanari, M., Balzarotti, M., Spina, M., Ilariucci, F., Zaja, F., Stelitano, C., Bobbio, F., Corazzelli, G., Baldini, L., Ponzoni, M., Picozzi, P., Cappio, F. C., & Reni, M. (2006). MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology, 66(9), 1435-1438. https://doi.org/10.1212/01.wnl.0000210464.94122.e1

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. / Ferreri, A. J M; Dell'Oro, S.; Foppoli, M.; Bernardi, M.; Brandes, A. A.; Tosoni, A.; Montanari, M.; Balzarotti, M.; Spina, M.; Ilariucci, F.; Zaja, F.; Stelitano, C.; Bobbio, F.; Corazzelli, G.; Baldini, L.; Ponzoni, M.; Picozzi, P.; Cappio, F. Caligaris; Reni, M.

In: Neurology, Vol. 66, No. 9, 05.2006, p. 1435-1438.

Research output: Contribution to journal › Article › peer-review

Ferreri, AJM, Dell'Oro, S, Foppoli, M, Bernardi, M, Brandes, AA, Tosoni, A, Montanari, M, Balzarotti, M , Spina, M , Ilariucci, F, Zaja, F, Stelitano, C, Bobbio, F, Corazzelli, G , Baldini, L , Ponzoni, M , Picozzi, P, Cappio, FC & Reni, M 2006, 'MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas', Neurology, vol. 66, no. 9, pp. 1435-1438. https://doi.org/10.1212/01.wnl.0000210464.94122.e1

Ferreri, A. J M ; Dell'Oro, S. ; Foppoli, M. ; Bernardi, M. ; Brandes, A. A. ; Tosoni, A. ; Montanari, M. ; Balzarotti, M. ; Spina, M. ; Ilariucci, F. ; Zaja, F. ; Stelitano, C. ; Bobbio, F. ; Corazzelli, G. ; Baldini, L. ; Ponzoni, M. ; Picozzi, P. ; Cappio, F. Caligaris ; Reni, M. / MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. In: Neurology. 2006 ; Vol. 66, No. 9. pp. 1435-1438.

@article{324e4da5d09449078cb5f6f483c06c0f,

title = "MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas",

abstract = "The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ± 7%) was obtained.",

author = "Ferreri, {A. J M} and S. Dell'Oro and M. Foppoli and M. Bernardi and Brandes, {A. A.} and A. Tosoni and M. Montanari and M. Balzarotti and M. Spina and F. Ilariucci and F. Zaja and C. Stelitano and F. Bobbio and G. Corazzelli and L. Baldini and M. Ponzoni and P. Picozzi and Cappio, {F. Caligaris} and M. Reni",

year = "2006",

month = may,

doi = "10.1212/01.wnl.0000210464.94122.e1",

language = "English",

volume = "66",

pages = "1435--1438",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "9",

}

TY - JOUR

T1 - MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

AU - Ferreri, A. J M

AU - Dell'Oro, S.

AU - Foppoli, M.

AU - Bernardi, M.

AU - Brandes, A. A.

AU - Tosoni, A.

AU - Montanari, M.

AU - Balzarotti, M.

AU - Spina, M.

AU - Ilariucci, F.

AU - Zaja, F.

AU - Stelitano, C.

AU - Bobbio, F.

AU - Corazzelli, G.

AU - Baldini, L.

AU - Ponzoni, M.

AU - Picozzi, P.

AU - Cappio, F. Caligaris

AU - Reni, M.

PY - 2006/5

Y1 - 2006/5

N2 - The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ± 7%) was obtained.

AB - The authors assessed MATILDE chemotherapy followed by response-tailored radiation therapy in 41 patients aged 70 years or younger with primary CNS lymphoma in a Phase II trial. With response rates of 76% after MATILDE and 83% after chemotherapy with or without radiation therapy, this was an active strategy, particularly in low- to intermediate-risk patients (International Extranodal Lymphoma Study Group [IELSG] score). Myelosuppression was the dose-limiting toxicity, with 9.5% of lethal complications. After a median follow-up of 49 months, a plateau in the survival curve (5-year overall survival: 41 ± 7%) was obtained.

UR - http://www.scopus.com/inward/record.url?scp=33646711027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646711027&partnerID=8YFLogxK

U2 - 10.1212/01.wnl.0000210464.94122.e1

DO - 10.1212/01.wnl.0000210464.94122.e1

M3 - Article

C2 - 16682682

AN - SCOPUS:33646711027

VL - 66

SP - 1435

EP - 1438

JO - Neurology

JF - Neurology

SN - 0028-3878

IS - 9

ER -

MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this